ExpreS2ion Biotech Holding

ExpreS2ion has announced its intention to carry out a rights issue of units of approximately SEK 53 million before transaction costs, with each unit consisting of one new share and one TO 13 warrant exercisable in September 2026 at 70% of the prevailing VWAP. The issue is secured to approximately 60% through subscription and guarantee commitments, with an extraordinary general meeting scheduled for 1 April 2026, subscription period expected 16–30 April, and final terms to be set no later than 6 April based on a TERP discount of at least 35%. Proceeds are primarily earmarked to complete the Phase I dose-escalation (expected mid-2026) and expansion cohort (late 2026) of lead candidate ES2B-C001, its HER2-targeted breast cancer vaccine.

Last week, ExpreS2ion published its FY 2025 results, which on the financial side showed continued low cost and cash burn levels compared to a year ago. Towards the end of 2025 and into the beginning of 2026, the company has shown progress on both its own pipeline and partner-led programs. The main candidate ES2B-C001, its HER2-targeted therapeutic breast cancer candidate, has continued to show promising but very early data, and the Malaria and Nipah programs have continued to move forward.

Today, ExpreS2ion Biotechnologies’ management presented the financial results for the FY 2025, provided further insights into the recent pipeline developments with focus on the malaria, Niphah and breast cancer candidates, and shared the latest updates on partnerships agreements

I dagens Morgenbørs ser vi ind i negative futures-markeder i Europa. Herhjemme er der fokus på regnskabsaktuelle ISS, Zealand Pharma, DFDS, Nilfisk og GomSpace.

ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company’s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&A session.

Dagens aktienyheder 19/02-2026: ISS, GomSpace, ExpreS2ion Biotechnologies og INVISIO

Mød ledelsen i ExpreS2ion Biotechnologies, GomSpace, ISS og INVISIO, og stil spørgsmål til dagens investorpræsentationer

Dagens aktienyheder 04/02-2026: Lundbeck, NORDEN og ExpreS2ion